

Ikena Oncology, Inc.  
645 Summer Street, Suite 101  
Boston, MA 02210

June 10, 2025

**VIA EDGAR**

Office of Life Sciences  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street NE  
Washington, D.C. 20549-3628

Attention: Ms. Christine Torney  
Ms. Lynn Dicker  
Mr. Daniel Crawford  
Mr. Alan Campbell

**Re: Ikena Oncology, Inc.  
Acceleration Request for Registration Statement on Form S-4  
File No. 333-285881**

**Requested Date: June 11, 2025  
Requested Time: 4:15 p.m. Eastern Time**

Dear Ms. Torney, Ms. Dicker, Mr. Crawford and Mr. Campbell:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Ikena Oncology, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 11, 2025, at 4:15 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Stephanie Richards at (617) 570-1927. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Stephanie Richards, by email to [srichards@goodwinlaw.com](mailto:srichards@goodwinlaw.com).

If you have any questions regarding this request, please contact Stephanie Richards of Goodwin Procter LLP at (617) 570-1927.

Sincerely,

Ikena Oncology, Inc.

/s/ Mark Manfredi

---

Mark Manfredi, Ph.D.

President and Chief Executive Officer

cc: Stephanie Richards, *Goodwin Procter LLP*  
John T. Haggerty, *Goodwin Procter LLP*  
Richard A. Hoffman, *Goodwin Procter LLP*  
Amanda Gill, *Goodwin Procter LLP*  
Lauren Visek, *Goodwin Procter LLP*

---